Evrysdi 60mg (Powder for Oral Solution) (Risdiplam)
Intended for healthcare professionals only
This material should not be used as a substitute for professional medical advice or to promote any medication. For more information, please consult your physician
Evrysdi is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Full prescribing information is available on request.
If you have a scientific query related to one of Roche's products, please contact us at [email protected]
In case of any adverse events or safety queries, please contact [email protected]
M-PK-00002297
Solutions
Pharma Products
![[Product] Evrysdi](https://assets.roche.com/f/169232/768x511/f6908beed5/everysdi.jpg/m/320x180/filters:format(webp):quality(90)/)